Vivos Therapeutics, Inc. (VVOS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated December 15, 2020, reports the consummation of the initial public offering (IPO) by Vivos Therapeutics, Inc., a Delaware corporation and emerging growth company. The report details the entry into material definitive agreements associated with the IPO.
Key Financial Metrics
- Shares Sold: 4,025,000 shares of Common Stock (including 525,000 shares from the full exercise of the underwriters' option).
- Offering Price: $6.00 per share.
- Gross Proceeds: $24,150,000 (before underwriting discounts, commissions, and offering expenses).
- Net Proceeds: The filing text does not provide a clear value for net proceeds after deducting expenses.
- Debt and Liquidity: The filing text does not provide specific data on existing debt, cash flow, or liquidity positions outside of the IPO proceeds.
Material Changes
The primary material change is the transition to a publicly traded company on The Nasdaq Stock Market LLC under the symbol "VVOS." Additionally, the Company entered into an Underwriting Agreement with Roth Capital Partners, LLC, and issued Representative's Warrants. A clarification was made regarding the term of the Representative's Warrants, extending them to five years from the effective date of the Registration Statement, rather than the previously indicated three years.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future performance, or specific risk factors beyond the standard disclosures inherent in an IPO filing. The document focuses strictly on the execution of the offering and the associated legal agreements.
Investor Verification Checklist
- Verify the final net proceeds after deducting underwriting discounts and offering expenses from the $24.15 million gross proceeds.
- Review the full Underwriting Agreement (Exhibit 1.1) for lock-up periods and indemnification terms.
- Examine the Representative's Warrant (Exhibit 4.1) to understand the exercise price and dilution impact of the five-year term.
- Confirm the Company's cash position and burn rate in the most recent audited financial statements filed in the S-1 Registration Statement.